MX344737B - Formas de rifaximina y sus usos. - Google Patents

Formas de rifaximina y sus usos.

Info

Publication number
MX344737B
MX344737B MX2012006275A MX2012006275A MX344737B MX 344737 B MX344737 B MX 344737B MX 2012006275 A MX2012006275 A MX 2012006275A MX 2012006275 A MX2012006275 A MX 2012006275A MX 344737 B MX344737 B MX 344737B
Authority
MX
Mexico
Prior art keywords
rifaximin
forms
hydrate
salt
relates
Prior art date
Application number
MX2012006275A
Other languages
English (en)
Inventor
S Gushurst Karen
Yang Donglai
Roe Melanie
Schultheiss Nathan
Vlahova Petinka
S Stults Jeffrey
l houston Travis
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX344737(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX344737B publication Critical patent/MX344737B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere al polimorfo, sal, hidrato, y las formas amorfas de rifaximina, a su uso en las preparaciones medicinales y a los métodos terapéuticos que las utilizan.
MX2012006275A 2008-02-25 2009-02-25 Formas de rifaximina y sus usos. MX344737B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3132908P 2008-02-25 2008-02-25
PCT/US2009/035192 WO2009108730A2 (en) 2008-02-25 2009-02-25 Forms of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
MX344737B true MX344737B (es) 2017-01-05

Family

ID=41016698

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010009389A MX2010009389A (es) 2008-02-25 2009-02-25 Formas de rifaximina y sus usos.
MX2012006275A MX344737B (es) 2008-02-25 2009-02-25 Formas de rifaximina y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010009389A MX2010009389A (es) 2008-02-25 2009-02-25 Formas de rifaximina y sus usos.

Country Status (21)

Country Link
US (7) US8067429B2 (es)
EP (1) EP2257557A4 (es)
JP (2) JP5706693B2 (es)
KR (1) KR101674382B1 (es)
CN (2) CN102015725B (es)
AU (1) AU2009219342B2 (es)
BR (1) BRPI0908864A2 (es)
CA (1) CA2716830C (es)
CR (2) CR11657A (es)
EA (2) EA021176B1 (es)
GE (1) GEP20135898B (es)
IL (1) IL207730A (es)
MA (1) MA32161B1 (es)
ME (1) ME01032B (es)
MX (2) MX2010009389A (es)
MY (1) MY158257A (es)
NZ (1) NZ587099A (es)
SG (2) SG10201607926VA (es)
UA (2) UA101829C2 (es)
WO (1) WO2009108730A2 (es)
ZA (2) ZA201005961B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG10201607926VA (en) 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
EP2350096B1 (en) 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1397107B1 (it) * 2009-12-28 2012-12-28 Lavagna Nuovo metodo per la preparazione di antibiotici in stato amorfo e prodotti ottenuti utilizzando detto metodo.
IT1399141B1 (it) * 2010-04-02 2013-04-05 Secci Metodo per la preparazione di rifaximina in stato amorfo.
IT1398550B1 (it) * 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
NZ603590A (en) * 2010-06-03 2015-08-28 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
AU2015203018B2 (en) * 2010-06-03 2016-10-20 Salix Pharmaceuticals, Ltd. New forms of rifaximin and uses thereof
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
EP3750526A1 (en) * 2010-07-12 2020-12-16 Salix Pharmaceuticals, Inc. Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
AU2012214239B2 (en) 2011-02-11 2016-06-30 Salix Pharmaceuticals, Ltd. Forms of Rifaximin and uses thereof
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110983A1 (it) * 2011-05-30 2012-12-01 A M S A Anonima Materie Sint & Affini S P A Amorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2986825T3 (es) * 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
EP2807148A4 (en) * 2012-01-25 2015-04-08 Salix Pharmaceuticals Ltd RIFAXIMIN DERIVATIVE AND USES THEREOF
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) * 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
JP2016516988A (ja) 2013-03-15 2016-06-09 アルファ ワッセルマン ソシエタ ペル アチオニＡｌｆａ Ｗａｓｓｅｒｍａｎｎ Ｓ．Ｐ．Ａ． 膣感染症を診断するための方法
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3140313B1 (en) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
KR102362719B1 (ko) 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
EP3902528A1 (en) * 2018-12-19 2021-11-03 Friulchem SpA Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
WO2024256873A1 (en) 2023-06-15 2024-12-19 Sebela Ireland Limited Methods of administering safe colon cleansing compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
CA2574307A1 (en) 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
KR101480732B1 (ko) 2006-09-22 2015-01-21 씨아이피엘에이 엘티디. 리팍시민
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US8383151B2 (en) 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
SG10201607926VA (en) 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
AU2009292615B2 (en) 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
CA2745980C (en) 2008-12-10 2017-10-31 Cipla Limited Rifaximin complexes
PE20121185A1 (es) 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
US8952159B2 (en) * 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
NZ603590A (en) 2010-06-03 2015-08-28 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
AU2012214239B2 (en) 2011-02-11 2016-06-30 Salix Pharmaceuticals, Ltd. Forms of Rifaximin and uses thereof

Also Published As

Publication number Publication date
US20120076857A1 (en) 2012-03-29
JP5706693B2 (ja) 2015-04-22
JP2015129168A (ja) 2015-07-16
MX2010009389A (es) 2010-11-22
AU2009219342B2 (en) 2014-10-30
UA113275C2 (xx) 2017-01-10
US20100239664A1 (en) 2010-09-23
SG10201607926VA (en) 2016-11-29
WO2009108730A3 (en) 2009-12-30
ZA201308527B (en) 2014-07-30
ME01032B (me) 2012-10-20
US20140011828A1 (en) 2014-01-09
WO2009108730A2 (en) 2009-09-03
EA201001372A1 (ru) 2011-04-29
SG188931A1 (en) 2013-04-30
CR20150401A (es) 2015-11-19
BRPI0908864A2 (pt) 2018-09-18
US8067429B2 (en) 2011-11-29
UA101829C2 (uk) 2013-05-13
US20160317507A1 (en) 2016-11-03
CN102015725B (zh) 2014-10-22
CA2716830A1 (en) 2009-09-03
ZA201005961B (en) 2018-11-28
US20110105550A1 (en) 2011-05-05
MA32161B1 (fr) 2011-03-01
IL207730A0 (en) 2010-12-30
AU2009219342A1 (en) 2009-09-03
EA201370208A1 (ru) 2014-06-30
US20150299199A1 (en) 2015-10-22
EP2257557A4 (en) 2011-06-29
CR11657A (es) 2010-11-22
MY158257A (en) 2016-09-30
KR101674382B1 (ko) 2016-11-09
US9700545B2 (en) 2017-07-11
EA021176B1 (ru) 2015-04-30
CN104650114A (zh) 2015-05-27
GEP20135898B (en) 2013-08-12
JP2011513243A (ja) 2011-04-28
US9359357B2 (en) 2016-06-07
CN102015725A (zh) 2011-04-13
US20130066079A1 (en) 2013-03-14
EP2257557A2 (en) 2010-12-08
IL207730A (en) 2016-04-21
NZ587099A (en) 2012-08-31
US9181274B2 (en) 2015-11-10
CA2716830C (en) 2019-01-08
US8754098B2 (en) 2014-06-17
KR20100127797A (ko) 2010-12-06

Similar Documents

Publication Publication Date Title
MY158257A (en) Forms of rifaximin and uses thereof
MY158992A (en) Forms of rifaximin and uses thereof
PH12018501404A1 (en) Forms of rifaximin and uses thereof
ZA201005201B (en) Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof
IL207078A (en) The history of azabiccal carboxamide, their preparation and their use for treatment
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
AU2011328009A8 (en) Compounds and methods for treating pain
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
ZA201100210B (en) Pyridino-pyridinone derivatives,preparation thereof,and therapeutic use thereof
IL209840A0 (en) Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL215103A0 (en) N-[(6-AZA-bicyclo[3.2.1]OCT-5-YL]-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME
IL209903A0 (en) Derivatives of 2-oxo-alkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
AP2011005798A0 (en) Use of ammonium chloride in therapy.
SI2421864T1 (sl) 1-pirazolo(4,3-c)izokinolinski derivati, njihova priprava in njihova terapevtska uporaba
IL214544A0 (en) Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof
EP2350212A4 (en) POLYAMINO-ACETONITRILES, PROCESSES FOR PREPARING THEM AND USE THEREOF
TN2010000377A1 (en) Forms of rifaximin and uses thereof